SLNSW-A phase I/II study of 10-min dosing of bendamusti...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

Full title: A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

Author/creator: Ishizawa, Kenichi, Yokoyama, Masahiro, Kato, Harumi, Yamamoto, Kazuhito, Makita, Masanori, Ando, Kiyoshi, Ueda, Yasunori, Tachikawa, Yoshimichi, Suehiro, Youko, Kurosawa, Mitsutoshi, Kameoka, Yoshihiro, Nagai, Hirokazu, Uoshima, Nobuhiko, Ishikawa, Takayuki, Hidaka, Michihiro, Ito, Yoshikiyo, Utsunomiya, Atae, Fukushima, Koji, Ogura, Michinori.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

Language: English

Formats: Articles

Publishers: Berlin/Heidelberg: Springer Berlin Heidelberg

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    Share

    A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

    Full title

    A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

    Author / Creator

    Ishizawa, Kenichi ; Yokoyama, Masahiro ; Kato, Harumi ; Yamamoto, Kazuhito ; Makita, Masanori ; Ando, Kiyoshi ; Ueda, Yasunori ; Tachikawa, Yoshimichi ; Suehiro, Youko ; Kurosawa, Mitsutoshi ; Kameoka, Yoshihiro ; Nagai, Hirokazu ; Uoshima, Nobuhiko ; Ishikawa, Takayuki ; Hidaka, Michihiro ; Ito, Yoshikiyo ; Utsunomiya, Atae ; Fukushima, Koji ; Ogura, Michinori

    Publisher

    Berlin/Heidelberg: Springer Berlin Heidelberg

    Journal title

    Cancer chemotherapy and pharmacology, 2022, Vol.90 (1), p.83-95

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    B-cell lymphoma Bendamustine Cancer Research Care and treatment Cell number Clinical trials Confidence intervals Dosage Hodgkin's disease Lymphocytes Lymphocytes B Lymphoma Lymphomas Mantle cell lymphoma Medicine Medicine & Public Health NCT NCT03900377 Non-Hodgkin lymphoma Oncology Original Original Article Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase I Rapid infusion Rituximab Safety Tolerability Toxicity

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300521

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Citation/abstract only (No full text) >

    View in old catalogue

    Connecting people and collections